|
NEJM Article: The Primary Outcome Fails — What Next?
|
6
|
Resverlogix Corp.
|
Sep 30, 2019 01:31PM
|
|
Re: Annual and Special Mtg & Corporate Update Presentation 12/22/20 - Rough Transcript
|
6
|
Zenith Epigenetics
|
Jan 05, 2021 01:01PM
|
|
Re: I'm as anxious as anyone for this train to get moving....thoughts on stonegate
|
6
|
Resverlogix Corp.
|
Nov 06, 2015 06:13PM
|
|
How common is this infectious pathway, or whatever the correct term is?
|
6
|
Resverlogix Corp.
|
Jan 03, 2021 08:27PM
|
|
Already posted by someone else??
|
6
|
Resverlogix Corp.
|
Sep 27, 2022 03:48AM
|
|
Dr. Kausik Ray on BETonMACE
|
6
|
Resverlogix Corp.
|
Dec 07, 2019 03:08PM
|
|
Re: Two Interesting Articles - 2 of 2: COVID-19: consider cytokine storm syndromes and immunosuppression
|
6
|
Resverlogix Corp.
|
Apr 13, 2020 08:03PM
|
|
Interesting....
|
6
|
Resverlogix Corp.
|
Aug 01, 2022 04:48AM
|
|
Abstracts 2 of 4: Cardiovascular Benefits of Apabetalone: A Meta-analysis
|
6
|
Resverlogix Corp.
|
Nov 09, 2020 03:25PM
|
|
Abstracts 4 of 4: Apabetalone (RVX-208) Reduces ACE2 Expression in Human Cell Culture Systems, Which Could Attenuate SARS-CoV-2 Viral Entry
|
6
|
Resverlogix Corp.
|
Nov 09, 2020 03:32PM
|
|
Re: Rought Transcript: RVX Presentation at GCFF Virtual Conference – Investing In Innovation – 09/10/2020
|
6
|
Resverlogix Corp.
|
Sep 19, 2020 06:37AM
|
|
Two on COVID and kidneys
|
6
|
Resverlogix Corp.
|
Sep 30, 2020 07:01PM
|
|
Re: Article Inflammation & CVD
|
6
|
Resverlogix Corp.
|
Jun 17, 2022 01:09PM
|
|
Re: Rough Transcript RVX 21_05_12_PBA_at_Noon...
|
6
|
Resverlogix Corp.
|
May 13, 2021 08:08AM
|
|
Re: #Covid19 Interview of Nevan Krogan, Director Quantitative Bioscience Institute QBI @UCSF
|
6
|
Resverlogix Corp.
|
Mar 27, 2020 03:05AM
|
|
COVID-19 and BRD4: a stormy and cardiotoxic bromo-romance
|
6
|
Resverlogix Corp.
|
Nov 10, 2021 10:40AM
|
|
Article: RVX-208 and substance abuse?
|
6
|
Resverlogix Corp.
|
Apr 13, 2022 05:58PM
|
|
Re: Downloaded presentation…
|
6
|
Resverlogix Corp.
|
Jun 22, 2021 06:14PM
|
|
Old News - New Article (in Cardiology Advisor dated Nov 4)
|
6
|
Resverlogix Corp.
|
Nov 05, 2020 06:58PM
|
|
Re: Health Canada Issues Resverlogix Authorization to Begin Immediate Clinical Studies of Apabetalone for COVID-19
|
6
|
Resverlogix Corp.
|
Apr 12, 2021 04:20PM
|
